SCHEMBL6985309

SCHEMBL6985309

CC(C)C[C@H](NC(=O)[C@H]1O[C@@H]1C(=O)O)C(=O)N1CCN(c2ccccc2Cl)CC1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CAPN1 P07384 6/20 0.54
ALDH1A1 P00352 3/20 0.50
KDM4E B2RXH2 2/20 0.50
NPSR1 Q6W5P4 1/20 0.50
HSD17B10 Q99714 1/20 0.49
CCR1 P32246 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
MC4R P32245 5/20 0.45
MAPK1 P28482 2/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
CAPN9 O14815 1/20 0.44
CTSB P07858 1/20 0.44
GAA P10253 1/20 0.43
TGM6 O95932 1/20 0.42
F13A1 P00488 1/20 0.42
TGM2 P21980 1/20 0.42
TGM1 P22735 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6985559 0.88 CAPN1 (0.58) CAPN1ALDH1A1KDM4ENPSR1HSD17B10
SCHEMBL6979028 0.87 SMN1; SMN2 (0.49) CAPN1ALDH1A1NPSR1CCR1SMN1; SMN2
SCHEMBL6979020 0.87 SMN1; SMN2 (0.49) CAPN1ALDH1A1NPSR1CCR1SMN1; SMN2
SCHEMBL6984615 0.86 KMT2A (0.51) ALDH1A1KDM4EHSD17B10CCR1SMN1; SMN2
SCHEMBL6981297 0.85 CAPN1 (0.50) CAPN1ALDH1A1KDM4ENPSR1HSD17B10
SCHEMBL6978563 0.85 CCR1 (0.50) ALDH1A1CCR1SMN1; SMN2KMT2A
SCHEMBL6981151 0.85 TGM2 (0.45) CAPN1ALDH1A1SMN1; SMN2MC4RMEN1
SCHEMBL6985150 0.85 NPSR1 (0.50) CAPN1ALDH1A1KDM4ENPSR1HSD17B10
SCHEMBL6982389 0.84 TGM2 (0.47) CAPN1ALDH1A1KDM4EHSD17B10CCR1
SCHEMBL10859034 0.84 CAPN1 (0.56) CAPN1ALDH1A1KDM4ENPSR1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6551999-B1 For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors SENJU PHARMACEUTICAL CO., LTD. (JP) 2003-04-22 US disclosed
EP-0771565-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-01-02 EP disclosed
US-6214800-B1 ANGIOGENESIS INHIBITORS SENJU PHARMACEUTICAL CO., LTD. (JP) 2001-04-10 US disclosed
US-6057290-A ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS SENJU PHARMACEUTICAL CO., LTD. (JP) 2000-05-02 US disclosed
EP-0928786-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-14 EP disclosed
EP-0927716-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-07 EP disclosed
EP-0838460-A1 PIPERAZINE DERIVATIVES AND USE OF THE SAME Senju Pharmaceutical Co., Ltd. (JP) 1998-04-29 EP disclosed
EP-0771565-A2 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1997-05-07 EP disclosed